SCHEMBL14914055

SCHEMBL14914055

CCc1ccccc1-c1ccc(C(=O)Nc2ccc(S(N)(=O)=O)c(OC)c2)cc1CO

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.49
▸ MAPT P10636 3/20 0.49
▸ STAT3 P40763 1/20 0.47
▸ TDP1 Q9NUW8 2/20 0.46
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ MCL1 Q07820 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ PLAU P00749 1/20 0.44
▸ PLAT P00750 1/20 0.44
▸ MCHR1 Q99705 2/20 0.43
▸ KLK7 P49862 1/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ OPRM1 P35372 1/20 0.42
▸ OPRD1 P41143 1/20 0.42
▸ CTDSP1 Q9GZU7 1/20 0.42
▸ NQO2 P16083 1/20 0.42
▸ CASP3 P42574 1/20 0.42
▸ SENP7 Q9BQF6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14914566 0.91 MCHR1 (0.49) POLBMAPTSTAT3TDP1MEN1
SCHEMBL14914056 0.91 STAT3 (0.52) POLBMAPTSTAT3TDP1MEN1
SCHEMBL10035051 0.89 MCHR1 (0.49) POLBMAPTSTAT3TDP1PLAU
SCHEMBL14914337 0.87 MEN1 (0.46) POLBMAPTSTAT3TDP1MEN1
SCHEMBL14915077 0.87 POLB (0.45) POLBMAPTSTAT3TDP1MEN1
SCHEMBL10035104 0.87 MAPT (0.45) POLBMAPTSTAT3TDP1
SCHEMBL14914955 0.87 PDE4A (0.45) POLBMAPTSTAT3TDP1MEN1
SCHEMBL10035273 0.86 POLB (0.43) POLBMAPTSTAT3TDP1MEN1
SCHEMBL14914410 0.85 MAPT (0.45) POLBMAPTSTAT3TDP1MEN1
SCHEMBL10035072 0.84 MAPT (0.48) POLBMAPTSTAT3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594554-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-05-22 — — EP claimed
US-20130116227-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-05-09 — — US claimed
EP-2594554-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-05-22 — — EP disclosed
US-20130116227-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116227-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF MC2R, NR3C2, REN POLB 4291/4885MAPT 4709/4885STAT3 690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback